Early Trial Data Show Promising Results for GM-CSF Blockade in CMML
Researchers are seeking to determine whether adding lenzilumab to standard-of-care treatment will improve outcomes in patients with CMML.
Diagnosis & Disease Information
Ponatinib Yields Benefits Across 3 Dosage Regimens in Chronic-Phase Chronic Myeloid Leukemia
Researchers sought to determine whether different doses of ponatinib would have benefit for patients with resistant chronic-phase chronic myeloid leukemia.
Adding Pevonedistat to Azacitidine Does Not Improve Outcomes for Patients With MDS/CMML and AML
Researchers sought to determine whether adding pevonedistat to azacitidine would improve outcomes for patients with higher-risk MDS, CMML, or AML.
HDMTX Promising for Patients With Primary CNS Lymphoma Ineligible for Clinical Trials
Researchers compared outcomes in patients with PCNSL who did not meet clinical trial criteria with those of patients from a major multicenter clinical trial of PCNSL.
Radotinib May Have Similar Efficacy to Imatinib in Chronic Myeloid Leukemia
Researchers reported long-term follow-up results from the phase 3 RERISE study, which assessed the efficacy of radotinib compared with imatinib for CML treatment.
Acquired von Willebrand Syndrome in Pediatric Patients With Chronic Myeloid Leukemia
Researchers assessed whether high platelet counts in pediatric patients with chronic myeloid leukemia resulted in thrombosis or bleeding.
Follow-Up Results of Low-Dose Dasatinib for Chronic-Phase Chronic Myeloid Leukemia
Patients received 50 mg dasatinib daily and demonstrated 2-year rates of overall and event-free survival of 100%.
Prognosis of Patients With Chronic Myeloid Leukemia Presenting in Advanced Phase
Factors associated with survival in chronic myeloid leukemia diagnosed in advanced phase or blast crisis included blast count, age, and hemoglobin level.
Study Compares Quality of Life for Patients With Chronic Myeloid Leukemia Treated With Dasatinib vs Imatinib
Using validated assessment tools, researchers compared patients’ perceptions of HRQOL while undergoing treatment for CML with 1 of 2 TKIs.
Making Treatment Decisions About Discontinuing TKIs in Chronic Myeloid Leukemia
Researchers are assessing the value and safety of discontinuing TKI therapy in patients with chronic phase CML who have achieved deep molecular response.
- Loading...
Loading...
Next post in Leukemia
Loading... 
Loading...